Tysabri Side Effects Explained by Neurologist

Website to estimate risk of PML with Tysabri: http://www.clinicspeak.com/understand...

I report no financial conflicts of interest

Comment or ask questions below! I would be happy to answer!

Subscribe on YouTube for more videos every Wednesday!

Make video requests in the comments section!

My book "Resilience in the Face of Multiple Sclerosis" on Amazon: https://www.amazon.com/dp/B07WP7H5LK

References:

• 1) Tysabri package insert; http://www.tysabri.com/pdfs/I61061-13...
• 2) “Natalizumab (Tysabri)”; D.T. Selewskia et al; AJNR 2010 31: 1588-1590
• 3) “Review article: clinically significant liver injury in patients treated with natalizumab (TYSABRI).” Aliment Pharmacol Ther 2010; 31: 1028–35. Epub 2010 Feb 16; Bezabeh S, Flowers CM, Kortepeter C, et al
• 4) “Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.” Rice GP, Hartung HP, Calabresi PA;Neurology 2005; 64: 1336–42
• 5) “Melanoma complicating treatment with natalizumab (Tysabri) for multiple sclerosis.” Ismail A, Kemp J, Sharrack B; J Neurol 2009; 256: 1771–72. Epub 2009 Jul 16
• 6) “Melanoma complicating treatment with natalizumab for multiple sclerosis.” Mullen JT, Vartanian TK, Atkins MB; N Engl J Med 2008; 358: 647–48
• 7) “Tysabri (Natalizumab) biologic license application 125104/15” Center for Drug Evaluation and Research (CDER). In: Proceedings of the Peripheral and Central Nervous System Drugs Advisory Committee, Gaithersburg, Maryland. 3 7–8,
• 8) “Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.” Clifford DB, DeLuca A, Simpson DM, et al; Lancet Neurol 2010; 9: 438–46
• 9) “A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.” Gordon FH, Lai CW, Hamilton MI, et al Gastroenterology 2001; 121: 268–74
• 10) “The pathophysiologic role of alpha 4 integrins in vivo.” Lobb RR, Hemler ME J Clin Invest 1994; 94: 1722–28
• 11) “Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients.” Fine AJ, Sorbello A, Kortepeter C, Scarazzini L.; Clin Infect Dis. 2013 Sep;57(6):849-52. doi: 10.1093/cid/cit376. Epub 2013 May 31.
• 12) “Natalizumab-induced autoimmune hepatitis in a patient with multiple sclerosis.” Mult Scler. 2013 Aug;19(9):1234-5. doi: 10.1177/1352458512463485. Epub 2012 Oct 15. Martínez-Lapiscina EH, Lacruz F, Bolado-Concejo F, Rodríguez-Pérez I, Ayuso T, Garaigorta M, Urman JM.
• 13) “Drug-induced thrombocytopenia secondary to natalizumab treatment.”; Cachia D, Izzy S, Berriosmorales I, Ionete C.
• BMJ Case Rep. 2014 May 30;2014. pii: bcr2013203313. doi: 10.1136/bcr-2013-203313
• 14) “Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.”; J Cent Nerv Syst Dis. 2014 Apr 28;6:41-9. doi: 10.4137/JCNSD.S14049. eCollection 2014; Hoepner R, Faissner S, Salmen A, Gold R, Chan A.
• 15) mouse doctor blog; http://multiple-sclerosis-research.bl...
• 16) "Osteopontin: role in immune regulation and stress responses". Cytokine Growth Factor Rev. 19 (5-6): 333–45. doi:10.1016/j.cytogfr.2008.08.001. PMID 18952487. Wang KX, Denhardt DT (2008).
• 17) "Fibronectin fragmentation promotes alpha4beta1 integrin-mediated contraction of a fibrin-fibronectin provisional matrix"Valenick LV, Hsia HC, Schwarzbauer JE (September 2005).. Experimental cell research 309 (1): 48–55. doi:10.1016/j.yexcr.2005.05.024. PMID 15992798.
• 18) “Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants.” Antioxid Redox Signal. 2011 Sep 15;15(6):1607-38. doi: 10.1089/ars.2010.3522. Epub 2011 May 11. Cook-Mills JM1, Marchese ME, Abdala-Valencia H.


Dr. Brandon Beaber is a board-certified neurologist with subspecialty training in multiple sclerosis and other immunological diseases of the nervous system.

Follow me on twitter:   / brandon_beaber  

Music: INNER GRACE - Copyright 2018 Wilton Vought

Source: Really Really Free Music

Link:    • Видео  

The video material by Dr. Brandon Beaber is general educational material on health conditions and is not intended to be used by viewers to diagnose or treat any individual's medical condition. Specifically, this material is not a substitute for individualized diagnostic and treatment advice by a qualified medical/health practitioner, licensed in your jurisdiction, who has access to the relevant information available from diagnostic testing, medical interviews, and a physical examination. To the extent that Dr. Beaber endorses any lifestyle change, behavioral intervention, or supplements, the viewer should consult with a qualified healthcare professional to determine the safety and efficacy of the intervention in light of their individualized information.